consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases
Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …
determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
Background Clinical application of therapeutic drug monitoring (TDM) to optimise anti‐TNF
therapies in patients with IBD depends upon target ranges. Aims To review methodology …
therapies in patients with IBD depends upon target ranges. Aims To review methodology …
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
Background The impact of pregnancy on levels of biologic agents in patients with IBD is
undefined and time to elimination in vedolizumab‐exposed infants is unknown. Aims To …
undefined and time to elimination in vedolizumab‐exposed infants is unknown. Aims To …
Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study
B Ungar, T Engel, D Yablecovitch, A Lahat… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Adalimumab is usually self-injected at home, making prospective serial-
sampling studies challenging and scarce. This has led to a gap in knowledge about …
sampling studies challenging and scarce. This has led to a gap in knowledge about …
Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a …
H Nakase, S Motoya, T Matsumoto… - Alimentary …, 2017 - Wiley Online Library
Background Significance of monitoring adalimumab trough levels and anti‐adalimumab
antibodies (AAA) for disease outcome in Crohn's disease (CD) patients remained unclear …
antibodies (AAA) for disease outcome in Crohn's disease (CD) patients remained unclear …
Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease—understanding pharmacokinetics and exposure response relationships in a …
CT-P13 is the first subcutaneous infliximab molecule approved for the management of
inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a …
inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a …
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors
MG Ward, B Warner, N Unsworth… - Alimentary …, 2017 - Wiley Online Library
Background Discriminative drug level thresholds for disease activity endpoints in patients
with Crohn's disease. have been consistently demonstrated with infliximab, but not …
with Crohn's disease. have been consistently demonstrated with infliximab, but not …
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn's disease
X Roblin, P Veyrard, L Bastide… - Alimentary …, 2022 - Wiley Online Library
The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT‐P13 results in
homogeneous serum trough concentrations of IFX at steady state. The present study aimed …
homogeneous serum trough concentrations of IFX at steady state. The present study aimed …
Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn's disease: a prospective multicentre study
N Vande Casteele, F Baert, S Bian… - Journal of Crohn's …, 2019 - academic.oup.com
Abstract Background and Aim Therapeutic drug monitoring is used to optimise adalimumab
therapy in patients with Crohn's disease [CD]. However, the interindividual variability in drug …
therapy in patients with Crohn's disease [CD]. However, the interindividual variability in drug …
Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era
S Schreiber, S Ben-Horin, R Alten, R Westhovens… - Advances in …, 2022 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has prompted significant
changes in patient care in rheumatology and gastroenterology, with clinical guidance issued …
changes in patient care in rheumatology and gastroenterology, with clinical guidance issued …